Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The cellular process of protein synthesis that is specifically disrupted by the action of Pseudomonas Exotoxin A (PE), a potent bacterial toxin produced by *Pseudomonas aeruginosa*. PE exerts its cytotoxic effect by irreversibly inhibiting eukaryotic protein synthesis, ultimately leading to cell death. PE enters target cells through receptor-mediated endocytosis, undergoes intracellular trafficking to the ER, translocates to the cytosol, and catalyzes ADP-ribosylation of elongation factor 2 (EF-2), an essential component for ribosomal translocation during mRNA translation. This modification inactivates EF-2, halting protein synthesis and triggering cell death. While PE itself is not a therapeutic target, the process of inhibiting protein synthesis by PE is relevant in the context of understanding bacterial pathogenesis and developing targeted therapies that exploit this mechanism.
ADP-ribosylation and inactivation of Elongation Factor 2 (EF-2)
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein synthesis machinery via Pseudomonas exotoxin-mediated inhibition.